<?xml version="1.0" encoding="UTF-8"?>
<p id="p0080">Amantadine first obtained FDA approval in 1966 under the brand name “Symmetrel” for systemic use in humans for prophylaxis of Asian influenza (H2N2) (
 <xref rid="bib28" ref-type="bibr">Davies et al., 1964</xref>; 
 <xref rid="bib111" ref-type="bibr">Schwab et al., 1969</xref>; 
 <xref rid="bib146" ref-type="bibr">Wingfield et al., 1969</xref>). However, during the first decade following its licensure, Symmetrel was not widely prescribed due in part to side effects such as agitation, confusion, and hallucinations (
 <xref rid="bib64" ref-type="bibr">Keyser et al., 2000</xref>). Additionally, the molecular mechanism describing a direct link between amantadine and virus inhibition was not described until more than 25 years later (
 <xref rid="bib34" ref-type="bibr">Duff and Ashley, 1992</xref>; 
 <xref rid="bib96" ref-type="bibr">Pinto et al., 1992</xref>). Rimantadine, sold under the brand name Flumadine, is a methylated derivative of amantadine which was licensed by FDA for the same indications in 1994.
</p>
